{
    "pmcid": "8448731",
    "qa_pairs": {
        "How does CeVICA enhance the neutralization potency of selected nanobodies?": [
            "By creating multivalent constructs",
            "By increasing the size of the nanobodies",
            "By reducing the molecular weight of the nanobodies",
            "By altering the nanobody's charge"
        ],
        "What is one of the potential future directions for the CeVICA platform mentioned in the summary?": [
            "Automation to enhance high-throughput antibody engineering",
            "Development of vaccines using nanobodies",
            "Integration with CRISPR technology",
            "Expansion to target bacterial infections"
        ],
        "What is the primary target of the nanobodies generated by the CeVICA platform?": [
            "The Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What method does CeVICA use to introduce mutations for affinity maturation?": [
            "Error-prone PCR",
            "Site-directed mutagenesis",
            "CRISPR-Cas9 editing",
            "Random chemical mutagenesis"
        ],
        "What technique does CeVICA use to link genotype and phenotype in its nanobody selection process?": [
            "Ribosome display",
            "Phage display",
            "Yeast surface display",
            "Bacterial display"
        ]
    }
}